Phase II study of EGFR-TKI rechallenge with afatinib in advanced NSCLC patients haboring sensitive EGFR mutation without T790M
Not Applicable
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000015568
- Lead Sponsor
- Okayama University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
1)SCLC and sarcoma peoven by rebiopsy 2)Symptomatic brain metastases 3)Leptomeningeal carcinomatosis 4)Active double cancer 5)Severe allergic history 6)Pregnancy 7)Svere complication 8)Indicated for urgent RT 9)Allergic history for afatinib 10)Inadequate patients whom physitians considered
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method